Kornimate/medical-research-clean huggingface dataset:
effect of oral nutritional supplements on body weight loss of patients with nasopharyngeal carcinoma

Conditions: Nasopharyngeal Carcinoma; Nutritional Support

Summary: concurrent chemoradiotherapy(ccrt) is the principal treatment for nasopharyngeal carcinoma(npc). studies have shown that malnutrition is very common in patients with npc after chemoradiotherapy. malnutrition can lead to weight loss, treatment interruption, prolonged stay in hospital, increased treatment costs, reduced tolerance to anti-tumor therapy, reduced quality of life and shortened survival time. nutritional intervention can improve the nutritional status, reduce treatment-related toxicity and improve the survival of patients with npc. the first choice of nutritional intervention is oral nutritional supplements(ons). some retrospective studies with small samples have found that early nutritional intervention can reduce weight loss and severe oral mucositis in patients with npc, compared with late nutritional intervention. therefore, the investigators proposed the hypothesis that ons from the beginning of radiotherapy can reduce the nutritional impairment, treatment-related toxicity and treatment costs of patients with npc, and improve their quality of life. the aim of this multicenter randomized controlled clinical trial is to evaluate the efficacy and cost utility of ons from the beginning to the end of radiotherapy.


Eligibility criteria:
inclusion criteria: * newly histologic diagnosis of nasopharyngeal carcinoma; * all genders, range from 18-70 years old; * clinical stage ii-iva according to the 8th edition of the union for international cancer control/american joint committee on cancer (uicc/ajcc) staging system; * patient-generated subjective nutrition assessment (pg-sga) score ≤8; * main organ functions test should be satisfied the following conditions: (1) absolute neutrophil count (anc) ≥1.5×10\^9/l; (2) platelet (plt) ≥80×10\^9/l; (3) hemoglobin (hb) ≥90 g/l; (4) bilirubin \ 60 ml/min. exclusion criteria: * patients whose energy intake is less than 60% of the target energy requirement for 3 days or more; * have or are suffering from other malignant tumors; * refuse concurrent chemoradiotherapy; * with diabetics, galactosemia, or sever metabolic diseases or endocrine diseases; * cannot take oral or enteral nutrition, including intestinal obstruction, severe short bowel syndrome or high output fistula, or with severe digestive system diseases; * known allergic reaction to any component of abbott®ensure, or severe allergic constitution; * pregnant or lactating women; * with previous or ongoing clinical trials; * refuse to sign inform consent form.

Keywords: nasopharyngeal carcinoma nutritional support chemoradiotherapy dietary supplements body weight cost-effectiveness analysis
mobile mindfulness training (mmt) for people in medication treatment of opioid use disorder (moud)

Conditions: Opioid Use Disorder

Summary: the goal of this clinical trial is to learn if mobile mindfulness training can help people in treatment for opioid use disorder. the main questions it aims to answer are: * will people with opioid use disorder and childhood trauma use mobile mindfulness training? * will mobile mindfulness training help people with opioid use disorder and childhood trauma have decreased markers of psychological stress? participants will: be given access to mobile mindfulness training and encouragement to use it daily for 30 days. keep a diary of how often mobile mindfulness training is used. visit the clinic four times to measure stress levels, including written rating scales, blood work, and heart rate tests.


Eligibility criteria:
inclusion criteria: * clinically diagnosed with opioid use disorder (per dsm5 criteria) * currently enrolled in treatment for opioid use disorder at a clinic affiliated with ukhealthcare or university of kentucky * on a stable dose of buprenorphine, buprenorphine/naloxone, or naloxone (i.e., at least 30 days post-induction and on a stable dose for 30 days) * able to read and understand english * have a history of childhood trauma as measured by the adverse childhood experiences scale and/or childhood trauma questionnaire. exclusion criteria: * currently taking a beta-blocker, calcium-channel blocker, antiarrhythmic, corticosteroid, or immune modulator medication * uncontrolled acute or chronic health conditions (e.g., active infections, autoimmune conditions, cancer undergoing active treatment) * current or expected pregnancy * current mindfulness practice (i.e., participant reports practicing mindfulness for 10 minutes or more per week) * primary psychotic illness * diagnosis of a disorder known to interfere with neurocognitive function (e.g., estimated full scale iq below 70 or diagnosis of dementia)

Keywords: opioid use disorder mindfulness childhood trauma treatment
the effect of sucrose on pain relief during venous blood sampling in preterm infants

Conditions: Pain

Summary: despite the fact that oral sucrose is the most frequently studied non-pharmacological intervention for procedural pain relief in infants, there is a paucity of data on the minimal effective dose. the aim of this study is to find the minimal effective dose of sucrose to reduce pain during a single venous blood sampling procedure.


Eligibility criteria:
inclusion criteria: * born preterm * more than 1000 gram exclusion criteria: * severe intraventricular hemorrhage * cerebral malformations * other malformations requiring surgery * medication that may impair pain expression (opioids, paracetamol, sedatives)

Keywords: sucrose anesthesia blood specimen collection injections, intravenous
the effect of deep brain stimulation on facial expressions.

Conditions: Parkinson

Summary: whether subthalamic nucleus (stn) deep brain stimulation (dbs), a treatment commonly used to ameliorate the motor symptoms of parkinson's disease (pd), affects on facial expressions is unclear. the purpose of this study was to investigate the potential effects of dbs and different frequencies on facial expressions of pd patients by volunteers via a web site: http://www.supporttoscience.com

parkinson's disease (pd) is the second most frequent progressive neuro-degenerative disease with a worldwide prevalence of 4-6 million and the mask face is an important and also troublesome sign of pd. deep brain stimulation (dbs) surgery can be a viable option which has recently emerged and been accepted as a useful surgical method for pd. standard dbs targets include subthalamic nucleus (stn) and globus pallidus internus (gpi). although the stn-dbs application is known to have favorable effects on motor and non-motor symptoms of pd, there is a lack information about the effect on facial expressions of pd patients. our aim is to analyze the effect of the stn-dbs stimulation and different frequencies on the facial expressions of pd patients. the study initially recruited 18 patients with idiopathic pd who underwent dbs surgery for movement disorders caused by pd at mustafa kemal university medical faculty neurosurgery department. inclusion criteria: * idiopathic pd responsive to l-dopa treatment, * between 40-75 years of age, * having received bilateral stn dbs surgery at least six months prior to the investigation to ensure stable stimulation parameters, * mentally normal patients that could understand and respond to a directives. the evaluation will be made by the face photos of the patients. the face photos for the expressions including \[normal\], \[sad\], \[happy\], and \[angry\] were obtained at frequencies including 130 hz, 60 hz, 99 hz, 230 hz and off-stimulation. the face photos will evaluate by the software and by the volunteers with the aim of a website: http://www.supporttoscience.com

Eligibility criteria:
inclusion criteria: * idiopathic pd responsive to l-dopa treatment, * between 40-75 years of age, * having received bilateral stn dbs surgery at least one month prior to the investigation to ensure stable stimulation parameters, * mentally normal patients that could understand and respond to a questionnaire. exclusion criteria: * above 75 years of age, * severe dementia, * history of an additional neurologic disease, * the presence of a disease, such as the facial paralysis, that could affect facial expressions, * having a wound on the face.

Keywords: parkinson's disease deep brain stimulation subthalamic nucleus dbs stn face facial expressions parkinson
piperacillin-tazobactam continuous versus intermittent infusion for pseudomonas aeruginosa

Conditions: Pseudomonas Aeruginosa Infection

Summary: the main objective is to verify that the administration of piperacillin / tazobactam administered by continuous infusion to treat complicated infections or with known or suspected nosocomial isolation of pseudomonas aeruginosa is superior in efficacy to a 30% higher dose administered in conventional short infusion. the secondary objectives were compared between the following variables: * microbiological response at 3 days of starting treatment * time to microbiological cure * clinical response at 3 days of starting treatment * time to achieve defervescence * to examine the relationship between pharmacokinetic variables and parameters of efficacy and safety * to test the hypothesis that continuous infusion maintains adequate plasma drug levels compared with levels achieved with intermittent administration. * cost-effectiveness analysis * occurrence of adverse effects to this end, we designed a multicenter, randomized, controlled, double blind, comparing both forms of administration in patients with complicated or nosocomial infection with or without isolation of pseudomonas aeruginosa. patients who are candidates for inclusion are classified according to apache ii and to have or not isolation of pseudomonas aeruginosa. subsequently be randomized to receive piperacillin-tazobactam by continuous infusion or short. primary endpoint was measured as the ultimate effectiveness of treatment and other variables such as high efficiency, safety, pharmacokinetic and pharmacoeconomic.


Eligibility criteria:
inclusion criteria: * complicated or nosocomial pseudomonas aeruginosa infection or suspected infection * \> 18 years and \> 40 kg * negative pregnancy test for women within fertile period * informed consent signature exclusion criteria: * life expectancy \< 72 hr * central nervous system (cns) infection * ventilator-associated pneumonia * severe neutropenia (\<500 cells/ml) * acinetobacter baumannii or extended spectrum beta lactamase (esbl) suspected infection * cystic fibrosis * shock * creatinine clearance \< 20 ml/min * dialysis or hemoperfusion

Keywords: pseudomonas piperacillin beta-lactams continuous infusion intermittent infusion pharmacokinetics
an open-label, dose-escalation study of azd2461

Conditions: Refractory Solid Tumors; Cancer Tumor

Summary: this study is being conducted to test study drug azd2461 to see how it may work to treat solid tumors. the main purpose of this study is to determine the safety and tolerability of azd2461. this is the first time the drug has been given to humans and is classed as a first time in man study. its main purpose is to establish a safe dosage of the drug and provide additional information on any potential side effects this drug may cause. the study will also assess the blood levels and action of azd2461 in the body over a period of time and will indicate whether the drug has a therapeutic effect on solid tumors.


Eligibility criteria:
inclusion criteria: * patients with confirmed diagnosis of solid tumor malignancy that is not responsive to standard therapies or for which there is no effective therapy. * eastern cooperative group (ecog) performance status score of 0 or 1 * patients must be 18 years of age * using adequate contraceptive measures, be surgically sterile or post-menopausal * patients entering this study must be willing to provide tissue from a previous tumor biopsy (if available) for correlative testing. if tissue is not available, a patient will still be eligible for enrollment into the study.. exclusion criteria: * patients currently receiving cancer therapy * use of investigation anti-cancer drug or major surgery, radiotherapy or immunotherapy with the last 21 days * cardiac disease

Keywords: refractory solid tumors cancer
physician-nurse team to reduce emergency department (ed) overcrowding

Conditions: Triage

Summary: the objective of this study is to explore the impact of a physician-nurse team supervising patient's flow on ed length of stay

a physician-nurse team will be in charge of patients flow in the ed during intervention periods. during control periods, no team will be present. the impact of this team on ed length of stay will be assessed.

Eligibility criteria:
inclusion criteria: * all adult patients \> 16 years presenting to the ed exclusion criteria: * no
red blood cell distributions (rdw, rdw-cw) and lymphocyte monocyte ratios (lmr) for the malignant thyroid nodules

Conditions: Thyroid Neoplasms Benign; Thyroid Nodule; Thyroid Cancer; Thyroid Diseases

Summary: thyroid surgery is the most common type of surgery among endocrine surgeries. this surgery is performed for patients with suspected malignancy, patients diagnosed with malignancy, and toxic nodular goiter. in addition to vocal cord injury, which is the most important complication of thyroid surgery, hypocalcemia due to hypoparathyroidism and surgical wound complications (such as hematoma, and fistula) can also be observed, and malignancy surgery increases the risk of recurrent laryngeal nerve injury. therefore, it is important to differentiate these groups using non-invasive methods before surgery. tumor-related inflammation is activated as a result of bone marrow and inflammation induced by malignancies. insufficiently controlled or uncontrolled inflammatory activity may be responsible for malignant transformation. lymphocyte monocyte ratio and red blood cell distribution are parameters (rdw, rdw-cw) previously studied in terms of cancers. our aim in this study is to reveal the rdw, rdw-cw, and lmr calculated from complete blood count parameters in the preoperative period, as an indicator of malignant inflammatory response, in a non-invasive and inexpensive way before surgery or biopsy is performed to distinguish nodular goiter and thyroid malignancy.

thyroid surgery patients older than 18 who were operated on at the department of general surgery of kahramanmaras sutcu imam university between january 2016 and january 2021 for nodular goiter and thyroid malignancy (surgical procedures include bilateral total thyroidectomy, unilateral total thyroidectomy, bilateral subtotal thyroidectomy, unilateral subtotal thyroidectomy, bilateral near total, completion thyroidectomy for recurrent cases). patients will be evaluated as malignant patients and patients with benign goiter diseases according to the pathology results. lymphocyte-monocyte ratios will be calculated manually by recording lymphocyte numbers, monocyte numbers, and red blood cell distribution volumes (rdw and rdw-cw) in the routine complete blood count values of the patients in the preoperative period. patient data will be accessed from the preoperative laboratory and postoperative pathology results recorded in patient epicrisis forms and the computer system.

Eligibility criteria:
inclusion criteria: * older than 18 age * thyroidectomy cases exclusion criteria: * younger than 18 age * patients with other system malignancies * patients with missing data
using an app in post oral cancer surgery to affect patients' needs and quality of life.

Conditions: Oral Cancer

Summary: this study aimed to explore using an app in post oral cancer surgery to affect patients' needs and quality of life. methods quasi-experimental research design used purposeful sampling from january 1 to december 31 of the far eastern memorial hospital oral maxillofacial surgery ward and the otolaryngology ward requirement met post-treatment oral cancer patients who agreed to participate. self-administered structured questionnaires, including basic personal information, cancer needs table short version (cnq-sf), head and neck cancer quality of life scale (eortc qlq-h\&n35), were used to collect information. results were statistically analyzed to understand the distribution of variables and their relationships. scientific or clinical implication of the expected results using an app intervention in post-operative patients with oral cancer may be the better way to promote health and enhance one's quality of life.

the malignant tumor has been consecutively ranked as number one of the top ten causes of death over the past 33 years, and the incidence of an increase in oral cancer year by year. the average age of death was 55-57. with this average age compared to other cancer patients under 10 years of early life, it's necessary to care about the burden of disease from oral cancer. the main treatment of oral cancer is surgery and a combination of radiotherapy and chemotherapy. patients often got severe treatment complications with varying degrees of physical functions and uncertainty due to poor cognition or less clarification in a complex course of treatment that affects medical decisions in the illness process. both domestic and foreign research show that the majority of oral cancer patients expressed the need for and attention to health information. "treatment information" was the most needed and important. when information needs are met, it can effectively reduce the anxiety and unease of unknown events. relevant domestic and foreign research do not provide accessibility and convenience of health education for post-operative patients with oral cancer.

Eligibility criteria:
inclusion criteria: * patients were diagnosed with oral cancer and were the first-time receiving oral cancer surgery within 1 week. * conscious and able o communicate * patients agreed to participate in this study and had a smart phone. exclusion criteria: * patients without oral cancer * patients with oral cancer but had received oral cancer surgery before 1 week or more. * unconscious or unable to answer questions from questionnaire or app * patients with cognitive impairment, dementia o intellectual disability.

Keywords: oral cancer、post-operation needs、quality of life、app
chloroquine + losartan compared to chloroquine alone for the treatment of covid-19 pneumonia

Conditions: COVID-19 Pneumonia

Summary: study design phase 2, double blinded, single-center, 1:1 randomized clinical trial of chloroquine vs chloroquine/losartan for the treatment of sars-cov-2 pneumonia in non-critically ill subjects

study design phase 2, blinded, single-center, 1: 1 randomized clinical trial for the treatment of sars-cov-2 pneumonia in non-critically ill subjects. two of the co-investigators and the data analyst will remain blind to group allocation until after statistical analysis. the groups will consist of subjects receiving in one arm po chloroquine 450mg every 12 hours and in the other arm, in addition to chloroquine, po losartan 25mg every 24 hours. study drugs will be administered for a total of 10 days enterally. baseline demographics and clinical characteristics will be registered and periodically during the study. nasopharyngeal swabs will be taken every 48hrs during hospitalization to determine the presences and viral load of sars-cov-2, and daily ekg for qt interval monitoring.

Eligibility criteria:
inclusion criteria: 1. men or women ≥18 years. 2. oral tolerance or access for enteral administration of medication. 3. pcr or igm for sars-cov-2 positive. 4. negative pregnancy test in case of a woman of reproductive age. 5. signature of a document proving informed consent. 6. hospital admission for sars-cov-2 pneumonia. exclusion criteria: 1. new alteration of the state of alert that does not revert after interventions 60 minutes after hospital admission. 2. mean arterial pressure (map) ≤ 65mmhg despite initial resuscitation on arrival at the centre. 3. history of allergy to chloroquine, hydroxychloroquine, piperaquine or primaquine. 4. known patient with hearing loss. 5. received chloroquine or hydroxychloroquine in the last 3 months. 6. patients with cirrhosis or elevation of aspartate transaminase (ast) or alanine transaminase (alt) greater than three times the upper normal limit. 7. patients with calculated glomerular filtration rate by modification of diet in renal disease study equation (mdrd) \< 30ml/min 1.73 m2. 8. patients known to be deficient in 6-phosphate dehydrogenase 9. patients known to have retinopathy or macular disease. 10. history of acute myocardial infarction in the last 6 months, unstable angina, ventricular tachycardia, ventricular fibrillation or class iii-iv heart failure according to new york heart association. 11. electrocardiogram qtc interval ≥ 480 ms. 12. patients with hypomagnesemia or uncorrected hypokalemia. 13. patients with a history of psychiatric illness. 14. patients who are pregnant or nursing. 15. patients taking quinolones, dextropropoxyphene, amiodarone, flecainide, cisapride, domperidone, atazanavir or lopinavir. 16. patients with acute pancreatitis. 17. patients who the investigators deem unsuitable for participation in the clinical trial.

Keywords: covid-19 sars-cov-2 pneumonia chloroquine phosphate losartan
an exploratory study to compare the differences in nutritional status between patients with mild and moderate alzheimer's disease (ad) and cognitively intact healthy people in an asian population

Conditions: Mild and Moderate Alzheimer's Disease; Cognitively Healthy People

Summary: difference in nutritional status between patients with mild and moderate alzheimer's disease (ad) and cognitively intact healthy people in an asian population

the main objective of the current asian nutritional status study is to get more insight into the nutritional status of ad patients in an asian population in asia. plasma levels of several micronutrients and the fatty acid profile will be compared between patients with mild and moderate ad and cognitively intact healthy controls in an asian population

Eligibility criteria:
inclusion criteria: * age ≥ 50 years old * asian ethnicity * group 1: cognitively intact healthy volunteers defined by cumulative illness rating scale for geriatrics rating of ≤ 2 for all categories except for the category "psychiatric illness" which should have a rating of 0 and a cdr of 0 within 1 year prior to the visit. or group 2a: ad patients clinically diagnosed with mild ad (according to the national institute of neurological and communicative disorders, and stroke-alzheimer's disease and related disorders criteria (mckhann et al., 1984)) with clinical dementia rating-1 or group 2b: ad patients clinically diagnosed with moderate ad (according to the national institute of neurological and communicative disorders, and stroke-alzheimer's disease and related disorders criteria (mckhann et al., 1984)) with clinical dementia rating-2 - written informed consent provided according to local regulations. exclusion criteria: * group 1 only: current diagnosis of ad or other dementias according to national institute of neurological and communicative disorders, and stroke-alzheimer's disease and related disorders criteria (mckhann et al.,1984 ) * group 2 only: change in dose within 2 months prior to visit of ad medication (e.g. donepezil, rivastigmine, galantamine or memantine) group 1 and 2: * diagnosis of significant neurological disease (for groups 2a and 2b: other than ad), including vascular dementia according to national institute of neurological and communicative disorders, and stroke-alzheimer's disease and related disorders criteria, cerebral tumour, huntington's disease, parkinson's disease, normal pressure hydrocephalus, seizures, major depression, schizophrenia and other entities * use of vitamins supplements (only vitamins supplements c and d are allowed) for 3 months prior to the visit * use of vitamin b injections * alcohol or drug abuse as per investigator's judgement * investigator's uncertainty about the willingness or ability of the patient to comply with the protocol requirements * participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study